The Latest Breaking News from HIV

In the U.S., Hispanic women have been disproportionately affected by the HIV epidemic in recent years. Yet they’ve been less likely to take advantage of PrEP, a medication that significantly reduces the risk of getting HIV.

World Health Organization warns outbreak in Africa resembles early days of HIV; percentage of income spend on mortgages has rocketed; giant Stonehenge stone came from Scotland

Outbreak resembles early days of HIV, say experts, urging accelerated access to vaccines and testing

The work of the late Stephen Cummins remains an archive of joy amid the gloom – and it’s screening at a Melbourne retrospective

A new Tennessee parental rights law could have unintended consequences in a state that already has seen rising cases of HIV and syphilis.

At 55, Sharif D Rangnekar stands at the intersection of several worlds – a journalist turned corporate professional, activist, and author of two books. Yet, it is his identity as a gay man and his role as a “facilitator” for the queer community that have defined his life narrative.  

Buoyed by encouraging clinical trial results and new advancements, the biotech industry is on a strong upward trajectory. Given the sector’s growing potential, I have highlighted three biotech stocks, Exelixis (EXEL), Gilead Sciences (GILD), and Halozyme Therapeutics (HALO), to consider before their second-quarter earnings report. Read on….

Diagnoses for sexually transmitted infections, or STIs, are increasing in older adults. The Centers for Disease Control and Prevention reports the number of people older than 65 diagnosed with chlamydia, gonorrhea or syphilis in the U.S. increased about three-, five- and sevenfold, respectively, from 2010 to 2023. Data also suggests…

Rise in gonorrhoea, syphilis and HIV rates partially due to reduced use of condoms across range of demographics, pathologists say

In South Africa, little research has been done on depression and anxiety among younger adolescents, those between the ages of 10 and 14. Existing studies have primarily targeted older adolescents and those living with HIV.

Recent results from a phase 3 trial reveal that a twice-yearly injection of the drug to treat AIDS offers 100% efficacy in preventing new infections.